ACTG A5146:IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE

ACTG A5146：治疗药物监测 (TDM) 对病毒学反应的影响

• 批准号: 7719430
• 负责人: THOMAS A CAMPBELL
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719430
• 关键词: Anti-HIV Agents; Anti-Retroviral Agents; Blood; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Monitoring; Funding; Grant; HIV; HIV Infections; HIV-1; Institution; Measures; Pharmaceutical Preparations; Protease Inhibitor; Protocols documentation; RNA; Research; Research Personnel; Resistance; Resources; Safety; Source; Specific qualifier value; Standards of Weights and Measures; Testing; Therapeutic; Therapeutic Uses; Treatment Protocols; United States National Institutes of Health; Viral Load result; Week; base; compare effectiveness; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will compare the effectiveness and safety of using increased doses of protease inhibitor (PI) drugs to continuing standard doses of PIs in lowering viral load (amount of HIV in the blood). The dose increases of the PI drugs will be based upon Therapeutic Drug Monitoring (TDM), which involves measuring blood levels of PIs. This study will also see if using an NIQ (normalized inhibitory quotient), a new way of using TDM to adjust the levels of anti HIV drug in the blood, helps control HIV infection better than not using the NIQ and TDM drug levels. Antiretroviral regimens will be selected and prescribed by the subject's clinician based on the results of the resistance testing. All subjects must initiate a salvage regimen at study entry that contains a PI at protocol-specified doses. Antiretroviral drugs will not be provided by this protocol. A5146 will provide resistance testing at baseline and for subjects who have confirmed HIV-1 RNA ¿ 1000 copies/mL at or after week 24.

这个子项目是众多研究子项目之一